Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02779777 · ClinicalTrials.gov registry record · Phase 2
Tipifarnib in Subjects With Myelodysplastic Syndromes
A Phase 2 study, sponsored by Kura Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02779777 is a Phase 2 study that was terminated before completion, run by Kura Oncology. The registered enrollment target is 16 participants.
The verdict
NCT02779777, a Phase 2 study, was terminated before completion, sponsored by Kura Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a Phase 2 randomized, open-label, two-stage study designed to investigate the antitumor activity of tipifarnib in approximately 36 eligible subjects with MDS who have no known curative treatment. Subjects will be randomized to receive tipifarnib orally with food according to one of 2 treatment regimens.
Interventions
- DRUG Tipifarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2018-08-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02779777
The ClinicalTrials.gov registry entry for NCT02779777 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kura Oncology, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tipifarnib is the first listed.
NCT02779777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02779777 about?
NCT02779777 is a clinical study titled "Tipifarnib in Subjects With Myelodysplastic Syndromes". This is a Phase 2 randomized, open-label, two-stage study designed to investigate the antitumor activity of tipifarnib in approximately 36 eligible subjects with MDS who have no known curative treatment. Subjects will be randomized to receive tipifarnib orally with food according to one of 2 treatme...
What is the current status of trial NCT02779777?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2016-06-01. Estimated completion is 2018-08-28.
What interventions are being tested in trial NCT02779777?
The interventions under investigation include: Tipifarnib (DRUG).
Who is sponsoring clinical trial NCT02779777?
This trial is sponsored by Kura Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.